Breast (Apr 2021)

Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: German HTA-driven analyses from the ExteNET study

  • D. Lüftner,
  • H. Tesch,
  • M. Schmidt,
  • A. Hartkopf,
  • S. Streicher,
  • A. Resch,
  • L. Genovese,
  • C. Rosé,
  • R. Valenti,
  • N. Harbeck

Journal volume & issue
Vol. 56
p. S17

Abstract

Read online

No abstracts available.